Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc > Replicel Top Investors
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(55)
•••
Post by Ingiboyon Nov 02, 2023 12:49pm
204 Views
Post# 35713900

Replicel Top Investors

Replicel Top InvestorsThe following 10 investors hold 62.7% (40,737,421 shares) of Replicels issued shares:

Top Investors

Name 
 
 
 % Held 
 
 
 Held 
 
 
 Held Change 
 
 
 Date 
 
 
 TurnOver 
 
 
Schutte (Andrew) 
26.77 
17,401,616 
0 
2023-08-23 
MED 
Mackay (Jamie) 
15.44 
10,034,537 
0 
2023-08-23 
LOW 
YOFOTO China Health Industry Co Ltd 
8.24 
5,357,900 
0 
2023-04-25 
LOW 
Mainpointe Pharmaceutical, L.L.C. 
6.13 
3,986,684 
0 
2023-04-25 
LOW 
McElwee (Kevin) 
2.04 
1,329,245 
670,833 
2022-12-31 
LOW 
Hall (David M) 
1.35 
875,632 
0 
2023-08-23 
LOW 
Lewis (Peter W) 
0.9645 
626,920 
17,500 
2023-08-23 
LOW 
Hoffman (Rolf) 
0.7532 
489,572 
0 
2022-12-31 
LOW 
Austring (Ben) 
0.4931 
320,500 
320,500 
2022-12-31 
 
Boddington (Gary) 
0.4843 
314,815 
0 
2023-08-23 
LOW 
 


I am sure that this group is not happy that the share price is currently at $.06.  I am also sure they are going to do whatever is necessary to protect their investment. So for those that are thinking of buying some cheap shares, this would be the time to do it because there is no way this group will let this company go under.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities